EC Approves Second Indication for AbbVie’s SKYRIZI November 19, 2021 Auto Bot News 0 AbbVie’s SKYRIZI (risankizumab) has gained approval for the treatment of active psoriatic arthritis in adults, which is the therapy’s second indication in the European Union.